- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04789655
Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1, Multi-center, Open-label, Dose Finding Study of CC-96191 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
This Phase 1, clinical study of CC-96191 will explore the safety, tolerability and preliminary biological and clinical activity of CC-96191 as a single-agent in the setting of Relapsed or refractory acute myeloid leukemia (R/R AML).
The dose escalation (Part A) of the study will explore escalating intravenous doses of CC-96191 to estimate the MTD and/or RP2D of CC-96191 as monotherapy.
The expansion (Part B), will further evaluate the safety and efficacy of CC-96191 administered at or below the MTD in one or more expansion cohorts in order to determine the RP2D.
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: BMS Study Connect Contact Center http://www.bmsstudyconnect.com
- Phone Number: 855-907-3286
- Email: Clinical.Trials@bms.com
Study Contact Backup
- Name: First line of the email MUST contain the NCT# and Site #
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4N2
- Recruiting
- Local Institution - 202
-
Contact:
- Site 202
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Recruiting
- Local Institution - 201
-
Contact:
- Site 201
-
-
-
-
-
Marseille cedex, France, 13273
- Recruiting
- Institut Paoli Calmette Hematologie
-
Contact:
- Sylvain Garciaz, Site 303
- Phone Number: 0491223333
-
Paris, France, 75010
- Recruiting
- Hopital Saint Louis
-
Contact:
- Emmanuel Raffoux, Site 304
- Phone Number: 33142499649
-
Pessac Cedex, France, 33604
- Recruiting
- Hopital Haut Leveque
-
Contact:
- Pierre Yves Dumas, Site 301
-
Villejuif CEDEX, France, 94805
- Recruiting
- Gustave Roussy
-
Contact:
- Stephane De Botton, Site 302
- Phone Number: +33 1 42 11 40 79
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Recruiting
- University of Alabama at Birmingham
-
Contact:
- Pankit Vachhani, Site 109
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Recruiting
- Mayo Clinic - Jacksonville
-
Contact:
- James Foran, Site 105
- Phone Number: 205-934-2248
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Winship Cancer Institute of Emory University
-
Contact:
- William Blum, Site 108
- Phone Number: 614-406-4123
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic
-
Contact:
- Mithun Shah, Site 110
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Recruiting
- Hackensack University Medical Center
-
Contact:
- Jaime Koprivnikar, Site 101
-
-
New York
-
New York, New York, United States, 10029
- Recruiting
- Mt. Sinai Medical Center Division of Hematology/Oncology
-
Contact:
- John Mascarenhas, Site 102
- Phone Number: 212-241-4106
-
-
Texas
-
Houston, Texas, United States, 77030-4009
- Recruiting
- The University of Texas - MD Anderson Cancer Center
-
Contact:
- Tapan Kadia, Site 107
- Phone Number: 713-563-3534
-
-
Washington
-
Seattle, Washington, United States, 98104
- Recruiting
- Swedish Cancer Institute
-
Contact:
- Daniel Egan, Site 111
- Phone Number: 617-699-2437
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Participants must satisfy the following criteria to be enrolled in the study:
1. Participant must understand and voluntarily sign an informed consent form (ICF) prior to any study-related assessments/procedures being conducted.
3. Participant is ≥ 18 years of age at the time of signing the ICF. 4. Relapsed or refractory CD33 positive AML at last visit as defined by the World Health Organization (WHO) Classification who have failed or who are ineligible for or have refused all available therapies for AML which may provide clinical benefit.
6. Participant has Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
7. At least 4 weeks (from first dose) has elapsed from donor lymphocyte infusion without conditioning.
8. Females and males must practice true abstinence or agree to contraceptive methods throughout the study, and during the safety follow-up period.
Exclusion Criteria:
The presence of any of the following will exclude a Participant from enrollment:
- Participant is suspected or proven to have acute promyelocytic leukemia (FAB M3) based on morphology, immunophenotype, molecular assay, or karyotype.
- Participant has received systemic anticancer therapy (including investigational therapy) or radiotherapy < 28 days or 5 half-lives, whichever is shorter, prior to the start of study treatment. Hydroxyurea is allowed to control peripheral leukemia blasts.
- Participants with prior autologous hematopoietic stem cell transplant who, in the investigator's judgment, have not fully recovered from the effects of the last transplant (eg, transplant-related side effects).
- Prior allogeneic HSCT with either standard or reduced intensity conditioning ≤ 6 months prior to dosing.
- Participants on systemic immunosuppressive therapy post HSCT at the time of screening, or with clinically significant graft-versus-host disease (GVHD). The use of topical steroids for ongoing skin or ocular GVHD is permitted.
- Participant has persistent, clinically significant non-hematologic toxicities from prior therapies which have not recovered to < Grade 2.
- Participant has or is suspected of having central nervous system (CNS) leukemia. Evaluation of cerebrospinal fluid is only required if CNS involvement by leukemia is suspected during screening.
- History of concurrent second cancers requiring active, ongoing systemic treatment.
- Participant is known seropositive or active infection with human immunodeficiency virus (HIV), or active infection with hepatitis B virus or hepatitis C virus.
- Impaired cardiac function or clinically significant cardiac diseases, as defined in the protocol .
- Participant is a pregnant or lactating female.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CC-96191
CC-96191 will be administered intravenously on a 28-day Cycle
|
CC-96191
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose limiting toxicities (DLTs)
Time Frame: Up to 42 days after the first dose
|
Are defined as toxicities that meet the protocol-specified criteria occurring within the DLT assessment window (Cycle 1, Days 1 to at least 28 and up to 42 days) that cannot be attributed to a clearly identifiable cause such as underlying illness, disease progression, other concurrent illness, or concomitant medication.
|
Up to 42 days after the first dose
|
Maximum tolerated dose (MTD)
Time Frame: Up to 35 days after the last dose
|
Is defined as the highest dose at which less than 33% of the population treated with CC-96191 experience a dose limiting toxicity (DLT) in the first cycle.
|
Up to 35 days after the last dose
|
Adverse Events (AEs)
Time Frame: Up to 35 days after the last dose
|
Type, frequency, seriousness, severity and relationship of AEs to CC-96191
|
Up to 35 days after the last dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete remission rate (CRR)
Time Frame: Up to approximately 2 years
|
As defined by the European Leukemia Net (ELN) AML response criteria.
|
Up to approximately 2 years
|
Objective response rate (ORR)
Time Frame: Up to approximately 2 years
|
As defined by the European Leukemia Net (ELN) AML response criteria.
|
Up to approximately 2 years
|
Progression-free survival (PFS)
Time Frame: Up to approximately 2 years
|
Is defined as the time from the first dose of CC-96191 to the first occurrence of disease progression or death from any cause.
|
Up to approximately 2 years
|
Overall survival (OS)
Time Frame: Up to approximately 2 years
|
Is measured as the time from the first dose of CC-96191 to death due to any cause.
|
Up to approximately 2 years
|
Duration of remission
Time Frame: Up to approximately 2 years
|
For subjects with best response of complete remission (CR) of any type, morphologic leukemia free state (MLFS) or partial remission (PR), duration of response (DOR) is measured from the time when criteria for CR/MLFS/PR are first met (whichever is first recorded) until the first date at which relapse, or progressive disease is objectively documented
|
Up to approximately 2 years
|
Time to remission
Time Frame: Up to approximately 2 years
|
Time from the date of first dose to the earliest date of any response (CR of any type, MLFS or PR)
|
Up to approximately 2 years
|
Pharmacokinetics - Cmax
Time Frame: Up to 35 days after last dose
|
Maximum serum concentration of drug
|
Up to 35 days after last dose
|
Pharmacokinetics - AUC
Time Frame: Up to 35 days after last dose
|
Area under the serum concentration time-curve
|
Up to 35 days after last dose
|
Pharmacokinetics - tmax
Time Frame: Up to 35 days after last dose
|
Time to peak (maximum) serum concentration
|
Up to 35 days after last dose
|
Pharmacokinetics - t1/2
Time Frame: Up to 35 days after last dose
|
Terminal half-life
|
Up to 35 days after last dose
|
Pharmacokinetics - CL
Time Frame: Up to 35 days after last dose
|
Total body clearance of the drug from the serum
|
Up to 35 days after last dose
|
Pharmacokinetics - Vss
Time Frame: Up to 35 days after last dose
|
Volume of distribution at steady-state
|
Up to 35 days after last dose
|
Presence of anti-drug antibodies (ADA)
Time Frame: Up to 35 days after last dose
|
Detection of anti-drug antibodies in participants
|
Up to 35 days after last dose
|
Frequency of anti-drug antibodies (ADA)
Time Frame: Up to 35 days after last dose
|
Frequency of anti-drug antibodies in participants
|
Up to 35 days after last dose
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CC-96191-AML-001
- U1111-1264-5412 (Registry Identifier: WHO)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Information relating to our policy on data sharing and the process for requesting data can be found at the following link:
https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia, Myeloid
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Betta Pharmaceuticals Co., Ltd.Not yet recruitingAcute Myeloid Leukemia LeukemiaChina
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Peking University People's HospitalBeijing JD Biotech Co. LTD.RecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
-
Xuzhou Medical UniversityRecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
-
Bio-Path Holdings, Inc.RecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryUnited States
-
Yale UniversityPfizerTerminatedACUTE MYELOID LEUKEMIAUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
Clinical Trials on CC-96191
-
CelgeneCompleted
-
Radboud University Medical CenterNorgineUnknownColorectal NeoplasmsNetherlands, Greece
-
Juno Therapeutics, Inc., a Bristol-Myers Squibb...Recruiting
-
Bristol-Myers SquibbWithdrawnAdvanced Solid TumorsSpain
-
CelgeneActive, not recruitingMultiple MyelomaSpain, Canada, United States
-
CelgeneCompleted
-
CelgeneCompletedHealthy VolunteersUnited States
-
CelgeneCompleted
-
CelgeneCompletedHealthy VolunteerUnited States
-
CelgeneCompleted